Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15 year follow up of a phase II study from MD Anderson Cancer Center

BACKGROUND: Mantle cell lymphoma remains an aggressive and incurable malignancy. Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival, particularly in younger adults. However, there have been no long-term follow-up results for pa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Haematol
Glavni autori: Chihara, Dai, Cheah, Chan Yoon, Westin, Jason R., Fayad, Luis E., Rodriguez, Maria Alma, Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry W., Wang, Michael L., Romaguera, Jorge E.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5471614/
https://ncbi.nlm.nih.gov/pubmed/26648336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13796
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items